Target intelligence / Profile preview

ATP-sensitive potassium channel (KATP channel) (K₊TP channel)

Target
K₊TP channel
Molecular classification
Ion channel
01

Overview

The ATP-sensitive potassium channel (K₊TP channel), composed of Kir6.2 and SUR1 subunits in pancreatic β-cells, serves as a key metabolic sensor that couples glucose levels to insulin secretion. At low glucose, open channels maintain hyperpolarization, suppressing Ca⁺² influx and insulin release; rising glucose boosts ATP/ADP ratios via glycolysis, closing channels to depolarize the membrane, activate voltage-gated Ca⁺² channels, and trigger insulin exocytosis in a biphasic manner. This glucose-stimulated insulin secretion (GSIS) mechanism is central to glucose homeostasis, with channel dysfunction implicated in diabetes: activating mutations cause neonatal diabetes by preventing closure, while impaired β-cell metabolism in type 2 diabetes reduces ATP generation and channel sensitivity. Therapeutically, sulfonylureas and meglitinides close K₊TP channels to enhance insulin release in diabetes management, though this risks hypoglycemia. Emerging insights highlight its role in oscillatory electrical activity and potential contributions to glucagon regulation in α-cells, underscoring its broad impact on islet function.

Other names
K₊TP channelATP-sensitive K⁺ channelKir6.2/SUR1 channel (pancreatic β-cell isoform)
02

Mechanism of action

Channel closure by increased ATP/ADP ratio from glucose metabolism, leading to depolarization, voltage-gated Ca⁺² channel opening, and insulin granule exocytosis Pharmacological closure by sulfonylureas binding to SUR1 subunit, mimicking ATP effect to promote insulin release

03

Biological functions

Metabolic sensing (couples glucose metabolism to electrical activity)Signal transduction (closure triggers membrane depolarization, Ca⁺² influx, and insulin exocytosis)Regulation of insulin secretion (glucose-stimulated insulin secretion, GSIS)
04

Disease associations

Diabetes mellitus (neonatal diabetes via activating mutations; type 2 diabetes via impaired metabolic closure)
05

Safety considerations

Hypoglycemia (from excessive channel closure and insulin secretion, especially with sulfonylureas)Neonatal diabetes risk from gain-of-function mutations causing persistent channel opening
06

Interacting drugs

Sulfonylureas (e.g., tolbutamide, glibenclamide; close the channel to stimulate insulin secretion)

2 more in the full profile.

Beyond the preview

Go deeper on ATP-sensitive potassium channel (KATP channel) (K₊TP channel).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-sensitive potassium channel (KATP channel) (K₊TP channel).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call